Navamedic ASA
Oslo Stock ExchangeTotal Valuation
Navamedic ASA carries a market capitalization of 400.49M, placing it among publicly traded companies globally. Its enterprise value stands at 71.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 400.49M |
| Enterprise Value | 71.33M |
Share Statistics
Navamedic ASA currently has 11.07M shares outstanding.
| Shares Outstanding | 11.07M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Navamedic ASA trades at a trailing price-to-earnings ratio of 37.40. The price-to-sales ratio is 0.35, and the price-to-book ratio stands at 8.22.
| PE Ratio | 37.40 |
| PS Ratio | 0.35 |
| PB Ratio | 8.22 |
| P/TBV Ratio | -4.49 |
| P/FCF Ratio | 1.54 |
| P/OCF Ratio | 1.57 |
Enterprise Valuation
| EV / Sales | 0.28 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 1.19 |
Financial Position
Navamedic ASA maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.62, indicating elevated leverage, while an interest coverage ratio of -5.09 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.09 |
| Quick Ratio | 0.27 |
| Debt / Equity | 12.62 |
| Debt / EBITDA | -1.15 |
| Interest Coverage | -5.09 |
Financial Efficiency
| Return on Equity (ROE) | -143.02 |
| Return on Assets (ROA) | -5.81 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.54 |
Taxes
| Income Tax | -1.59M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Navamedic ASA's stock has declined approximately -25.11211% over the past 52 weeks. The 50-day moving average sits at 19.34, while the 200-day moving average is 21.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -25.11211% |
| 50-Day Moving Average | 19.34 |
| 200-Day Moving Average | 21.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Navamedic ASA generated 257.92M in revenue and converted that into -15.54M in net income, yielding earnings per share of -1.40. EBITDA reached -10.57M, while operating income came in at -10.57M.
| Revenue | 257.92M |
| Gross Profit | 70.27M |
| Operating Income | -10.57M |
| Pretax Income | -17.13M |
| Net Income | -15.54M |
| EBITDA | -10.57M |
| EBIT | -10.57M |
| Earnings Per Share (EPS) | -1.40 |
Balance Sheet
Navamedic ASA holds 30.25M in cash and equivalents against 12.21M in total debt, resulting in a net debt position of -18.04M. Total book value stands at 10.87M, with working capital of 9.54M providing operational flexibility.
| Cash & Cash Equivalents | 30.25M |
| Total Debt | 12.21M |
| Net Debt | -18.04M |
| Equity (Book Value) | 10.87M |
| Book Value Per Share | 0.98 |
| Working Capital | 9.54M |
Cash Flow
Navamedic ASA produced 57.10M in operating cash flow over the past twelve months. After subtracting -985,000.00 in capital expenditures, free cash flow totaled 56.11M - equivalent to 5.07 per share.
| Operating Cash Flow | 57.10M |
| Capital Expenditures | -985,000.00 |
| Free Cash Flow | 56.11M |
| FCF Per Share | 5.07 |
Margins
Navamedic ASA operates with a gross margin of 27.25, reflecting its pricing power and cost economics. The operating margin of -4.10 and net profit margin of -6.03 provide insight into operational efficiency.
| Gross Margin | 27.25 |
| Operating Margin | -4.10 |
| Pretax Margin | -6.64 |
| Profit Margin | -6.03 |
| EBITDA Margin | -4.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 52.20 |
| FCF Yield | 65.00 |
Scores
Navamedic ASA posts an Altman Z-Score of 2.15, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.15 |